{"result": "(\"entity\"<|>CYP3A4<|>ORGANIZATION<|>CYP3A4 is an important enzyme involved in the metabolism of cortisol, with significant variability among individuals.)\n##\n(\"entity\"<|>RIFAMPICINA<|>ORGANIZATION<|>Rifampicina is a drug that can induce the CYP3A4 enzyme, affecting cortisol metabolism.)\n##\n(\"entity\"<|>MITOTANO<|>ORGANIZATION<|>Mitotano is a drug that can induce the CYP3A4 enzyme, impacting cortisol levels.)\n##\n(\"entity\"<|>ANTICUERPOS ANTI-CTLA4<|>ORGANIZATION<|>Anti-CTLA4 antibodies, such as ipilimumab, are used to treat advanced tumors and can cause autoimmune hypophysitis.)\n##\n(\"entity\"<|>IPILIMUMAB<|>ORGANIZATION<|>Ipilimumab is a drug that targets CTLA-4 and is used in melanoma treatment, potentially causing autoimmune side effects.)\n##\n(\"entity\"<|>NIVOLUMAB<|>ORGANIZATION<|>Nivolumab is an immune checkpoint inhibitor that can be combined with ipilimumab for enhanced treatment effects.)\n##\n(\"entity\"<|>ATEZOLIZUMAB<|>ORGANIZATION<|>Atezolizumab is an immune checkpoint inhibitor targeting PD-L1, used in various cancers.)\n##\n(\"entity\"<|>AVELUMAB<|>ORGANIZATION<|>Avelumab is an immune checkpoint inhibitor that targets PD-L1, used in cancer treatment.)\n##\n(\"entity\"<|>DURVALUMAB<|>ORGANIZATION<|>Durvalumab is an immune checkpoint inhibitor that targets PD-L1, utilized in cancer therapies.)\n##\n(\"entity\"<|>MELANOMAS<|>EVENT<|>Melanomas are a type of skin cancer that can be treated with immune checkpoint inhibitors like ipilimumab and nivolumab.)\n##\n(\"entity\"<|>CARCINOMA DE CÉLULAS RENALES<|>EVENT<|>Renal cell carcinoma is a type of kidney cancer that can be treated with immune checkpoint inhibitors.)\n##\n(\"entity\"<|>CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS<|>EVENT<|>Non-small cell lung cancer is a type of lung cancer that can be treated with immune checkpoint inhibitors.)\n##\n(\"relationship\"<|>RIFAMPICINA<|>CYP3A4<|>Rifampicina induces the CYP3A4 enzyme, affecting cortisol metabolism<|>7)\n##\n(\"relationship\"<|>MITOTANO<|>CYP3A4<|>Mitotano induces the CYP3A4 enzyme, impacting cortisol levels<|>7)\n##\n(\"relationship\"<|>IPILIMUMAB<|>ANTICUERPOS ANTI-CTLA4<|>Ipilimumab is an anti-CTLA4 antibody used to treat advanced tumors<|>8)\n##\n(\"relationship\"<|>NIVOLUMAB<|>ANTICUERPOS ANTI-CTLA4<|>Nivolumab is an anti-CTLA4 antibody used in combination with ipilimumab<|>8)\n##\n(\"relationship\"<|>ATEZOLIZUMAB<|>ANTICUERPOS ANTI-CTLA4<|>Atezolizumab is an immune checkpoint inhibitor used in cancer treatment<|>6)\n##\n(\"relationship\"<|>AVELUMAB<|>ANTICUERPOS ANTI-CTLA4<|>Avelumab is an immune checkpoint inhibitor used in cancer treatment<|>6)\n##\n(\"relationship\"<|>DURVALUMAB<|>ANTICUERPOS ANTI-CTLA4<|>Durvalumab is an immune checkpoint inhibitor used in cancer treatment<|>6)\n##\n(\"relationship\"<|>MELANOMAS<|>IPILIMUMAB<|>Ipilimumab is used to treat melanomas<|>9)\n##\n(\"relationship\"<|>CARCINOMA DE CÉLULAS RENALES<|>IPILIMUMAB<|>Ipilimumab is used to treat renal cell carcinoma<|>9)\n##\n(\"relationship\"<|>CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS<|>IPILIMUMAB<|>Ipilimumab is used to treat non-small cell lung cancer<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: en terapéutica humana.\n         A. Actividad biológica hormonal alterada.                                                                                  El CYP3A4 es una enzima importante en el metabolismo del cortisol, aunque presenta\n         B. Alteración del receptor hormonal.                                                                                       una gran variedad entre diferentes individuos. Puede ser inducida por fármacos como\n         C. Anomalías posreceptor.                                                                                                  la rifampicina, el mitotano y varios agentes anticonvulsivos. En estos casos puede ser\n         D.  Aumento cuantitativo del receptor.                                                                                     necesario aumentar la dosis de fármacos u hormonas que utilizan esta enzima para su\n                                                                                                                                    metabolismo, como el cortisol en pacientes que lo reciben por insuficiencia                           suprarrenal.\n                                                                                                                                    Por otro lado, la enzima puede ser inhibida por algunos antifúngicos y antibióticos ma-\n         COMENTARIO                                                                                                                 crólidos, en cuyo caso se deberían reducir las dosis de cortisol.\n         La resistencia hormonal es consecuencia de una reducida o ausente respuesta de un ór-                                      Los inhibidores del punto de control (check point) son anticuerpos inmunomoduladores\n         gano efector a una hormona biológicamente activa, lo que perturba su actividad biológica.                                  que se utilizan para estimular el sistema inmunológico, con el fin de tratar tumores malig-\n         La mayor parte de las veces, los síndromes de resistencia hormonal son originados por una                                  nos avanzados. Tienen dos dianas:\n         alteración genética que da lugar a una ausencia o disminución del receptor, a una modifi-                                  •  Receptor de muerte celular programado-1 (PD-1) y ligando de muerte-celular pro-\n         cación de su estructura con menor afinidad a su ligando, o a una alteración en la respuesta                                   gramada 1 (PD-L1): a través de estos receptores actúan el nivolumab y el pembroli-\n         del mecanismo efector posreceptor.                                                                                            zumab, dirigidos al PD-1, y el atezolizumab, avelumab y durvalumab, dirigidos al PD-L1.\n         Para compensar dicha alteración se suele encontrar una concentración normal o elevada                                         Se utilizan en melanomas, carcinoma de células renales y cáncer de pulmón de células\n         en la circulación de la hormona afectada a pesar de signos clínicos de una deficiencia o una                                  no pequeñas, entre otros.\n         ausencia de acción hormonal.                                                                                               •  Antígeno 4 asociado a los linfocitos T citotóxicos (CTLA-4): a través de estos recep-\n                                                                                                                                       tores actúan el ipilimumab, dirigido contra el CTLA-4, que se utiliza en el melanoma y el\n         Referencias:                                                                                                                  carcinoma de células renales.\n         • Rojas JA, Céspedes C. Síndromes de resistencia hormonal por patología de receptores: mecanismos moleculares y fenotipos\n           clínicos. Rev Esp Endocrinol Pediatr. 2014;5(2):37-49.                                                                   Como resultado         de  la activación del sistema inmunitario, los inhibidores del punto de\n                                                                                                                                    control    pueden      producir    efectos    adversos inmunorrelacionados               dermatológicos,        gas-\n                                                                                                                                    trointestinales, hepáticos, neurológicos, endocrinológicos y otros menos comunes. Con\n     43  ¿Cuál de los siguientes enunciados es cierto?                                                                              el tratamiento médico adecuado, las reacciones adversas inmunorrelacionadas se resuel-\n         A. Los fármacos que inhiben la actividad del citocromo CYP3A4 aumentan la inactivación                                     ven en la mayoría de los casos. El ipilimumab puede asociarse al nivolumab, lo que tam-\n             del cortisol y, por tanto, es necesario aumentar las dosis sustitutivas en la insuficiencia                            bién puede aumentar los efectos adversos (tabla 7).\n             suprarrenal.                                                                                                           Tabla 7. Endocrinopatías por ipilimumab y nivolumab\n         B. El mitotano es un inhibidor del citocromo CYP3A4.                                                                                                  Frecuentes (1-10%): hipopituitarismo (incluyendo hipofisitis) e hipotiroidismo\n         C. Los anticuerpos anti-CTLA4 como el ipilumumab pueden ocasionar hipofisitis                                                                         Poco frecuentes (1%-1/1.000): insuficiencia suprarrenal, hipertiroidismo\n             autoinmune (y así, insuficiencia suprarrenal secundaria).                                                                                         e hipogonadismo\n         D.  Los tres enunciados son ciertos.                                                                                         Endocrinopatías\n                                                                                                                                      con ipilimumab           Raras (1/1.000-1/10.000): tiroiditis\n                                                                                                                                                               Suspensión permanente del tratamiento: 2,9%\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}